Structure Encountered
AvenCell Therapeutics
Developing switchable allogeneic CAR-T platform for hematological cancers and autoimmune diseases
AvenCell's AVC-203 is the first CRISPR-engineered allogeneic CAR-T with a switchable receptor to hit the clinic — and the timing couldn't be better.
SIGNAL·CLINICAL PULSE·SCORE 93·02 APR 2026 · 20:18 UTC
● CAPTURE — IMAGE INCOMINGFRAME 01 / 01
STRUCT. / AVENCELL THERAPEUTICS
CAPT. / 02.04.26 20:18:44Z
SIGNAL / 93 / 100
Image relayed by The Biotech Voyager during pass over structure AvenCell Therapeutics. Resolution as transmitted.
001Vital Statistics
DATA LOCKED
Designation
AvenCell Therapeutics
Stage
Phase 2
Type
Therapeutics
Modalities
CAR-T · cell therapy · allogeneic · autologous
Therapeutic area
Oncology · Hematology · Autoimmune
003Architecture
AWAITING ENRICHMENT
Target class · differentiator · lead asset · pipeline depth populate once the writer fills these fields on this row.
004Voyager Assessment
STRUCTURE PROFILE
<cite index="3-5,5-6">AvenCell Therapeutics was founded in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics.</cite> <cite index="3-2">The company is building a cell therapy platform that targets difficult-to-treat cancers, with lead programs focusing on acute myeloid leukemia (AML) and B-cell malignancies, and additional programs targeting other hematological malignancies, auto-immune diseases, and solid tumors.</cite> <cite index="3-3">AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient.</cite> <cite index="14-8,14-9">The company's switchable or "universal" CAR-T platform uses engineered T cells with a universal receptor that is only activated when bound to a targeting module, allowing for on and off control of therapeutic activity.</cite> <cite index="8-16">The company is currently active as a private company.</cite>
005Tags
HOUSTON CLASSIFIED
Clinical PulseAVC-203CAR-TallogeneicCRISPR
— End of transmission —This signal was received and processed by The Biotech Voyager and HOUSTON. Transmissions are auto-generated from public sources and platform telemetry. They are not edited for prose. For human analysis and connection to other signals, watch the Tuesday or Thursday mission broadcast aboard the [SHIP]. Field notes — long-form synthesis from the crew — are archived separately.